Share Name Share Symbol Market Type Share ISIN Share Description
Integrated Diagnostics Holdings Plc LSE:IDHC London Ordinary Share JE00BLKGSR75 ORD USD0.25
  Price Change % Change Share Price Shares Traded Last Trade
  0.008 1.06% 0.76 45,530 16:35:16
Bid Price Offer Price High Price Low Price Open Price
0.754 0.764 0.77 0.76 0.77
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 246.05 105.13 11.07 7.4 114
Last Trade Time Trade Type Trade Size Trade Price Currency
17:02:34 O 362 0.75991 USD

Integrated Diagnostics (IDHC) Latest News

More Integrated Diagnostics News
Integrated Diagnostics Investors    Integrated Diagnostics Takeover Rumours

Integrated Diagnostics (IDHC) Discussions and Chat

Integrated Diagnostics Forums and Chat

Date Time Title Posts
21/6/202217:34Integrated Diagnostics34
19/8/201820:55Integrated Diagnostics (IDHC) One to Watch on Monday -

Add a New Thread

Integrated Diagnostics (IDHC) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Integrated Diagnostics trades in real-time

Integrated Diagnostics (IDHC) Top Chat Posts

Integrated Diagnostics Daily Update: Integrated Diagnostics Holdings Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker IDHC. The last closing price for Integrated Diagnostics was US$0.75.
Integrated Diagnostics Holdings Plc has a 4 week average price of US$0.75 and a 12 week average price of US$0.75.
The 1 year high share price is US$1.45 while the 1 year low share price is currently US$0.75.
There are currently 150,112,360 shares in issue and the average daily traded volume is 393,213 shares. The market capitalisation of Integrated Diagnostics Holdings Plc is £114,085,393.60.
tomps2: IDHC pitched in the latest episode of Sell It To The City Neil Cooper pitches Integrated Diagnostic Holdings (IDHC) to leading fund managers, Andy Brough, Judith MacKenzie and Stephen English at 25m47s in the latest PIWORLD Sell It To The city. Watch the video here: Or listen to the podcast here:
brucie5: What no interest??? hTTps:// "Profitability came in at an all-time high, with adjusted EBITDA 1 growing 116% year-on-year to record EGP 2,530 million, and net profit recording a 145% year-on-year increase to reach EGP 1,493 million in FY 2021. In the final quarter of the year, IDH reported revenue of EGP 1,458 million, 48% above the previous year's figure, and net profit of EGP 345 million, up 47% from the comparable three month period of 2020. It is important to note that information in relation to the Company's full year results has been extracted from our audited annual report. Meanwhile, disclosures and statements in respect of quarterly information are unaudited. In light of IDH's outstanding performance for the twelve months ended 31 December 2021, IDH's board of directors has recommended a dividend distribution of EGP 2.17 per share, or EGP 1.3 billion in aggregate, to shareholders (exact US dollar amount is subject to the exchange rate at the time of the upstreaming from the subsidiaries to the holding company). This represents a significant increase compared to a final dividend of US$ 29.1 million distributed for the previous financial year."
brucie5: Anyone else noticing/enjoying this chart? Given all that's going down in Kazakhstan atm, with implications for dividend favourites CAML and STCM, IDHC looks a relatively tranquil option...
brucie5: Yes, I hear a lot of peeps saying that this is too risky for their folios, but if you hold shares like CEY, WEN and FXPO, which I currently do, then adding a bit more geographical diversity may not be foolish, even if there is of course, country specific risk. IDHC ranks very highly on Stocko. I hope to be a holder for some time, unless I see good reason for selling. Chart also looks positive, btw, though not sure how much you can read into that...
rabiddog: Yeah still here. If it’s hq wasn’t in Egypt would be double the price…but it is lol.
valhamos: Good H1 results today. Although there has been an uplift in the share price it is difficult to work out what the bottom line would be without the impact of Covid which creates some uncertainty as to how one values the company. However it is stated that non Covid test revenue has grown 38% on H1 2020 but the prior period had been affected by reduced testing so comparing with H1 2019 shows underlying non Covid growth of 17%.
johnthespacer: The gbp/usd exchange rate is basically all that has happened the sterling has strengthened and because these are in usd the price drops... so when the usd earnings are changed to sterling the stronger pound means they get less £ per $ Hope this helps
johnthespacer: Final results out today look great! Am I the only one interested in this share??
trytotakeiteasy: written up here:
ncooper1: I'd welcome views as to why IDHC share price continues to fall. Fundamentals seem good, and the only obvious areas is Egypt being unsettled (but this is not new news). Currencies need to be considered too: essentially Egyptian Pound depreciating vs US$ and also £ depreciating relative to US$. My understanding is that the former should not impact IDHC input costs to the extent of share price fall-and the latter should mean the share price should increase, I think!? I've personally continued to add, but views sought.
Integrated Diagnostics share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220702 17:55:55